Learning Objectives:
- Identify the neurotransmitter, hormonal, and genetic factors that contribute to psychotropic-induced sexual dysfunction and differentiate medication effects from disease-related and non-psychiatric causes.
- Compare the sexual dysfunction profiles of antidepressants, antipsychotics, and mood stabilizers to select agents with lower risk based on clinical trial evidence.
- Apply a stepwise management approach — including modifiable factor assessment, medication substitution, and adjunctive antidote strategies — to individualize treatment while maintaining psychiatric stability.
Original Release Date: April 01, 2026
Expiration Date: April 01, 2029
Faculty: Anita Clayton, M.D.
Medical Editor: Tomás Abudarham, M.D.
Relevant Financial Disclosures:
Anita Clayton declares the following interests:
– Janssen: Grants/Research Contracts
– Neumora Therapeutics
– Neurocrine Biosciences
– Otsuka
– Relmada Therapeutics, Inc.
– Reunion Neuroscience, Inc.
– S1 Biopharma
– Autobahn Therapeutics
– Daré Bioscience
– AbbVie, Inc.: Advisory Board Fee/Consultant Fee
– Actinogen
– AdhereTech
– Axsome Therapuetics
– Biogen, Inc.
– Fabre-Kramer Pharmaceuticals
– Initiator Pharma
– Intra-cellular Therapies
– Janssen Research & Development, LLC
– LIVANOVA PLC
– MycoMedica Life Sciences, PBC
– P/S/L Group Services
– Seaport Therapeutics
– Sirtsei Pharmaceuticals, Inc.
– Vella Bioscience, Inc.
– Royalties/Copyright: Ballantine Books/Random House
– Changes in Sexual Functioning Questionnaire
– Guilford Publications
– Shares/Restricted Stock Units: Mediflix LLC
All the relevant financial relationships listed above have been mitigated by Medical Academy and the Psychopharmacology Institute.
None of the other faculty, planners, and reviewers for this educational activity has relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com
Instructions for Participation and Credit:
Participants must complete the activity online within the valid credit period noted above.
Follow these steps to earn CME credit:
- View the required educational content provided on this course page.
- Complete the Post-Activity Evaluation to provide the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
- Download your certificate.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Medical Academy designates this enduring activity for a maximum of 1 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Artificial Intelligence (AI) Use Disclosure
Artificial intelligence (AI) tools may have been used in limited stages of developing this activity (e.g., drafting or language refinement). The specific tool, version, and date of use are documented internally.
AI does not determine clinical recommendations. All content is reviewed, verified, and approved by the listed faculty and medical editors, and reflects independent human clinical judgment consistent with ACCME Standards for Integrity and Independence in Accredited Continuing Education.
